




Supplemental figure 4.



A, Boxplot showing the analysis of the AR Δ UTR variant (in RPKM) from VCaP xenografts treated with enzalutamide. **B**, Graph showing analysis results of AR Δ UTR (RPKM) from C4-2 cells treated with enzalutamide. **C**, Graph showing analysis results of AR Δ UTR (RPKM) from the MR49F cell line – grown in castrated mice and enzalutamide treated. **D**, Screenshot from Cuffmerge data analysis from metastatic deposits of a patients with disease progression. **E**, Screenshot from Cuffmerge data analysis from LNCaP-abl cells.